The NHS and ministers face two main challenges as they try to keep the UK’s vaccination rollout on track, after regulators advised that adults under the age of 30 should be offered alternatives to Oxford/AstraZeneca.
The AstraZeneca jab is the most widely used in the UK’s vaccination programme, so curtailing its use and lining up alternative supplies for young adults could have an impact on the supply chain.
The other issue is the risk that further publicity about a link between rare blood disorders and the jab will increase vaccine hesitancy in the UK, where people have been notably more receptive to vaccination than in most other European countries.
您已閱讀12%（657字），剩余88%（4693字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。